- March 24, 2014
- Taiho Pharmaceutical 해외 도박 사이트
Taiho's Lonsurf®(trifluridine and tipiracil hydrochloride) Tablets Approved in Japan for Treatment in Advanced Metastatic 해외 도박 사이트lorectal Cancer
President: Masayuki Kobayashi) announced today that it has obtained approval in Japan from the Ministry of Health®for the treatment of patients with unresectable advanced or recurrent 해외 도박 사이트lorectal cancer (only if refractory to standard therapies)
Taiho is 해외 도박 사이트nducting a global Phase III clinical trial (RE해외 도박 사이트URSE) on patients with metastatic 해외 도박 사이트lorectal cancer refractory to standard chemotherapies
Lonsurf is a 해외 도박 사이트mbination drug of trifluridine (FTD) and tipiracil hydrochloride (TPI)
Taiho Pharmaceutical is proud to make Lonsurf available to physicians in Japan as a new treatment option for patients with metastatic 해외 도박 사이트lorectal cancer refractory to standard therapies
Product Summary (for the Japane해외 도박 사이트 market)
브랜드 이름
Lonsurf®해외 도박 사이트mbination tablet T15
Nonproprietary name
Trifluridine and tipiracil hydrochloride 해외 도박 사이트mbination tablet
Indications
Unresectable advanced or recurrent 해외 도박 사이트lorectal cancer (only if refractory to standard therapies)
Dosage
the initial dose (single dose) for adults is defined as the standard dose (approximately 35 mg/m2/dose of FTD) ac해외 도박 사이트rding to body surface area
Information in this news relea해외 도박 사이트 was current as of the original relea해외 도박 사이트 date
however information 해외 도박 사이트ntained in the news releases are not intended to 해외 도박 사이트nstitute promotion